Department of Pediatrics, University of Alabama, 9380 Women and Infants Center, 1700 Sixth Ave S, Birmingham, AL 35249, USA.
JAMA. 2011 Dec 7;306(21):2348-58. doi: 10.1001/jama.2011.1752.
Current guidelines, initially published in 1995, recommend antenatal corticosteroids for mothers with preterm labor from 24 to 34 weeks' gestational age, but not before 24 weeks due to lack of data. However, many infants born before 24 weeks' gestation are provided intensive care.
To determine if use of antenatal corticosteroids is associated with improvement in major outcomes for infants born at 22 and 23 weeks' gestation.
DESIGN, SETTING, AND PARTICIPANTS: Cohort study of data collected prospectively on inborn infants with a birth weight between 401 g and 1000 g (N = 10,541) born at 22 to 25 weeks' gestation between January 1, 1993, and December 31, 2009, at 23 academic perinatal centers in the United States. Certified examiners unaware of exposure to antenatal corticosteroids performed follow-up examinations on 4924 (86.5%) of the infants born between 1993 and 2008 who survived to 18 to 22 months. Logistic regression models generated adjusted odds ratios (AORs), controlling for maternal and neonatal variables.
Mortality and neurodevelopmental impairment at 18 to 22 months' corrected age.
Death or neurodevelopmental impairment at 18 to 22 months was significantly lower for infants who had been exposed to antenatal corticosteroids and were born at 23 weeks' gestation (83.4% with exposure to antenatal corticosteroids vs 90.5% without exposure; AOR, 0.58 [95% CI, 0.42-0.80]), at 24 weeks' gestation (68.4% with exposure to antenatal corticosteroids vs 80.3% without exposure; AOR, 0.62 [95% CI, 0.49-0.78]), and at 25 weeks' gestation (52.7% with exposure to antenatal corticosteroids vs 67.9% without exposure; AOR, 0.61 [95% CI, 0.50-0.74]) but not in those infants born at 22 weeks' gestation (90.2% with exposure to antenatal corticosteroids vs 93.1% without exposure; AOR, 0.80 [95% CI, 0.29-2.21]). If the mothers had received antenatal corticosteroids, the following events occurred significantly less in infants born at 23, 24, and 25 weeks' gestation: death by 18 to 22 months; hospital death; death, intraventricular hemorrhage, or periventricular leukomalacia; and death or necrotizing enterocolitis. For infants born at 22 weeks' gestation, the only outcome that occurred significantly less was death or necrotizing enterocolitis (73.5% with exposure to antenatal corticosteroids vs 84.5% without exposure; AOR, 0.54 [95% CI, 0.30-0.97]).
Among infants born at 23 to 25 weeks' gestation, antenatal exposure to corticosteroids compared with nonexposure was associated with a lower rate of death or neurodevelopmental impairment at 18 to 22 months.
现行指南最初于 1995 年发布,建议对 24 至 34 孕周有早产迹象的孕妇使用产前皮质类固醇,但由于缺乏数据,不建议在 24 孕周前使用。然而,许多在 24 孕周前出生的婴儿都接受了强化护理。
确定在 22 至 23 孕周出生的婴儿中,使用产前皮质类固醇是否与主要结局的改善相关。
设计、地点和参与者:前瞻性队列研究,纳入了 1993 年 1 月 1 日至 2009 年 12 月 31 日期间在美国 23 个学术围产中心出生的体重在 401 至 1000 克之间、胎龄在 22 至 25 周之间的婴儿,共 10541 例。在婴儿出生后 18 至 22 个月进行随访检查的是 4924 例(86.5%),他们在 1993 年至 2008 年期间存活下来。采用 logistic 回归模型生成调整后的优势比(AOR),控制了母婴变量。
校正胎龄 18 至 22 个月时的死亡率和神经发育障碍。
在接受产前皮质类固醇治疗并在 23 孕周出生的婴儿中(暴露于产前皮质类固醇的婴儿死亡率或神经发育障碍为 83.4%,未暴露的婴儿为 90.5%;AOR,0.58[95%CI,0.42-0.80])、在 24 孕周出生的婴儿中(暴露于产前皮质类固醇的婴儿死亡率或神经发育障碍为 68.4%,未暴露的婴儿为 80.3%;AOR,0.62[95%CI,0.49-0.78])和在 25 孕周出生的婴儿中(暴露于产前皮质类固醇的婴儿死亡率或神经发育障碍为 52.7%,未暴露的婴儿为 67.9%;AOR,0.61[95%CI,0.50-0.74]),但在 22 孕周出生的婴儿中并未发现这种情况(暴露于产前皮质类固醇的婴儿死亡率或神经发育障碍为 90.2%,未暴露的婴儿为 93.1%;AOR,0.80[95%CI,0.29-2.21])。如果母亲接受了产前皮质类固醇治疗,那么在 23、24 和 25 孕周出生的婴儿中,以下情况发生的概率显著降低:18 至 22 个月时死亡;院内死亡;死亡、脑室出血或脑室周围白质软化;死亡或坏死性小肠结肠炎。对于在 22 孕周出生的婴儿,唯一显著降低的结局是死亡或坏死性小肠结肠炎(暴露于产前皮质类固醇的婴儿死亡率或神经发育障碍为 73.5%,未暴露的婴儿为 84.5%;AOR,0.54[95%CI,0.30-0.97])。
在 23 至 25 孕周出生的婴儿中,与未暴露相比,产前皮质类固醇暴露与校正胎龄 18 至 22 个月时的死亡率或神经发育障碍发生率较低相关。